New drug combo aims to stop liver Cancer's return after transplant
NCT ID NCT02081755
Summary
This study is testing if adding a drug called everolimus to standard anti-rejection medications after a liver transplant can better prevent liver cancer from coming back. It will involve about 336 adults with advanced liver cancer who receive a transplant. Researchers will compare two different drug combinations to see which one leads to longer survival without cancer recurrence.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, HEPATOCELLULAR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baylor University Medical Center
Dallas, Texas, 75246, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Mount Sinai Medical Center
New York, New York, 10029, United States
-
Northwestern University School of Medicine
Chicago, Illinois, 60611, United States
-
University of California at San Francisco
San Francisco, California, 94143, United States
-
University of Kansas Medical Center
Kansas City, Kansas, 66160, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
University of Tennessee- Methodist University Hospital
Memphis, Tennessee, 38104, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.